ULTIMOVACS

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs that require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe and the USA. The company and its proprietary technology are based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway.

#SimilarOrganizations #People #Website #More

ULTIMOVACS

Social Links:

Twitter

Industry:

Biotechnology Health Care Pharmaceutical

Founded:

2011-01-01

Address:

Oslo, Oslo, Norway

Country:

Norway

Website Url:

http://www.ultimovacs.com

Total Employee:

11+

Status:

Active

Email Addresses:

[email protected]

Total Funding:

270 M NOK

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Sitelinks Search Box Euro Organization Schema

Similar Organizations

apellis-pharmaceuticals-logo

Current Employees Featured

Øyvind-k-arnesen_image

Øyvind K. Arnesen
Øyvind K. Arnesen CEO @ Ultimovacs
CEO

Founder

Øyvind-k-arnesen_image

Øyvind K. Arnesen

Stock Details

Company's stock symbol is OSE:ULTI

Official Site Inspections

http://www.ultimovacs.com Semrush global rank: 5.82 M Semrush visits lastest month: 1.43 K

Host Informations
Whois Informations

Loading ...